NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: VENUSREM · data 2026-10-31
Venus Remedies Limited
In plain words
Price: 39.4% below its 52-week high of ₹2,044.3.
Delivery: 58.1% of traded shares were kept for delivery over the last 10 sessions, against 64.1% over the last 60.
Latest results: a net profit of ₹26 cr for the quarter ended Sept 2026 (+27.4% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹837 cr |
| Net profit (last 12 months) | ₹122 cr |
| Sales growth, 3 years (yearly) | 10.1% |
| Profit growth, 3 years (yearly) | 57.0% |
At a glance
Promoters 41.8% (unchanged in a year), pledged 0.0%, institutions 3.9%.
P/E 13.6, P/B 2.4, dividend yield 0.8%. Price relative to earnings and book value (low is cheaper, not better).
ROE 16.8%, ROCE 14.5%, operating margin 17.7%: how much profit it earns on the money it uses.
Debt/equity 0.02, Profit growth 57.0% and sales growth 10.1% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- Profit grew 57.0% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY27)
VENUSREM Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹218.76 crore, up 13.5% YoY and up 22.3% QoQ.
Net profit was ₹25.65 crore, up 27.4% YoY and up 11.7% QoQ.
Operating margin was 19.4% (16.1% a year ago).
EPS was ₹19.19, up 27.4% YoY and up 11.7% QoQ.
VENUSREM के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹218.76 करोड़; पिछले साल की तुलना में 13.5% की बढ़त, पिछली तिमाही की तुलना में 22.3% की बढ़त।
शुद्ध मुनाफ़ा: ₹25.65 करोड़; पिछले साल की तुलना में 27.4% की बढ़त, पिछली तिमाही की तुलना में 11.7% की बढ़त।
ऑपरेटिंग मार्जिन: 19.4% (एक साल पहले 16.1%)।
EPS: ₹19.19; पिछले साल की तुलना में 27.4% की बढ़त, पिछली तिमाही की तुलना में 11.7% की बढ़त।
VENUSREMના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹218.76 કરોડ; ગયા વર્ષની સરખામણીએ 13.5% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 22.3% વધારો.
ચોખ્ખો નફો: ₹25.65 કરોડ; ગયા વર્ષની સરખામણીએ 27.4% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 11.7% વધારો.
ઓપરેટિંગ માર્જિન: 19.4% (એક વર્ષ પહેલાં 16.1%).
EPS: ₹19.19; ગયા વર્ષની સરખામણીએ 27.4% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 11.7% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Too few delivery days to compare delivery % (0 of 10); shares delivered not comparable (0 of 12); 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 26 Oct 26Results Q2 FY27 results: profit +27.4% YoY -1.1% next session
- 7 Aug 26Dividend Dividend ₹10 (ex-date) -2.6% next session
- 20 Jul 26Results Q1 FY27 results: profit +139.3% YoY +0.3% next session
- 26 May 26Results Q4 FY26 results: profit +126.1% YoY +7.3% next session
- 29 Jan 26Results Q3 FY26 results: profit +30.5% YoY +9.8% next session
- 10 Nov 25Results Q2 FY26 results: profit +471.9% YoY +19.0% next session
- 1 Aug 25Results Q1 FY26 results: profit +686.9% YoY -2.4% next session
- 26 May 25Results Q4 FY25 results: profit +93.9% YoY +13.2% next session
- 4 Feb 25Results Q3 FY25 results: profit +186.1% YoY +21.8% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹219 cr | ₹26 cr | +27.4% | 19.4% | 19.19 |
| Jun 2026 | ₹179 cr | ₹23 cr | +139.3% | 19.1% | 17.18 |
| Mar 2026 | ₹259 cr | ₹47 cr | +126.1% | 24.4% | 35.53 |
| Dec 2025 | ₹180 cr | ₹26 cr | +30.5% | 20.8% | 19.14 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 41.76% | 41.76% | 41.76% | 41.76% |
| Foreign institutions (FII) | 3.14% | 2.92% | 2.80% | 2.26% |
| Domestic institutions (DII) | 0.74% | 0.89% | 1.20% | 1.03% |
| Mutual funds | 0.00% | — | — | — |
| Retail investors | 31.87% | 31.32% | 31.23% | 32.18% |
| Number of shareholders | 22,968 | 21,905 | 18,403 | 18,606 |
Common questions
What was Venus Remedies Limited's latest quarterly profit?
Venus Remedies Limited reported a net profit of ₹26 cr for the quarter ended Sept 2026 (+27.4% on the same quarter a year earlier), on revenue of ₹219 cr.
How much do promoters hold in Venus Remedies Limited?
Promoters held 41.76% of Venus Remedies Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Venus Remedies Limited debt-free?
Its latest reported debt-to-equity ratio is 0.02, which is very low.
What is Venus Remedies Limited's P/E ratio?
About 13.6, based on the last 12 months' earnings and a price of ₹1,238.6 (data 2026-10-31).
What is the 52-week high and low of Venus Remedies Limited?
The 52-week high is ₹2,044.3 and the 52-week low is ₹433.7.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Venus Remedies Limited | ₹1,238.6 | ₹1,646 cr | 13.6 | 2.4 | 16.8% | 14.5% | 0.02 | +182.9% |
| Panacea Biotec Limited | ₹313.25 | ₹1,917 cr | — | — | -0.6% | -6.3% | 0.03 | -29.8% |
| Windlas Biotech Ltd. | ₹876.1 | ₹1,810 cr | 28 | — | 12.2% | 13.5% | 0.06 | -8.4% |
| Syncom Formulation (India) Ltd. | ₹19.24 | ₹1,810 cr | 21.2 | — | 20.2% | 16.3% | 0 | +16.0% |
| NGL Fine-Chem Ltd. | ₹2,526 | ₹1,576 cr | 27.3 | — | 15.7% | 17.1% | 0.37 | +66.0% |
| Accent Microcell Limited | ₹639 | ₹1,533 cr | 26.9 | 5 | 18.7% | 22.7% | 0 | +140.2% |
Compare VENUSREM with PANACEABIO in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open VENUSREM in NSE Scanner →